Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis

Dermatology

Volumn 224, Issue 1, 2012, Pages 20-21

  Nishioka, Tatsuya ^a   Shinohara, Masayuki ^a   Tanimoto, Noriyasu ^a   Kumagai, Chizuru ^a   Hashimoto, Kozo ^a  

^a Hosogi Hospital   (Japan)

Author keywords

CD26; Diabetes mellitus; Dipeptidyl peptidase IV; Psoriasis; Sitagliptin

Indexed keywords

C PEPTIDE; CYCLOSPORIN; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN; STEROID; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CASE REPORT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSORIASIS VULGARIS; SKIN PIGMENTATION;

ADULT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; PSORIASIS; PYRAZINES; T-LYMPHOCYTES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84861097924     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000333358     Document Type: Article

References (8)

1. Ansorge S, Nordhoff K, Bank U, Heimburg A, Julius H, Breyer D, Thielitz A, Reinhold D, Täger M: Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem 2011; 392: 153-168.
2. Balci A, Balci DD, Yonden Z, Korkmaz I, Yenin JZ, Celik E, Okumus N, Egilmez E: Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology 2010; 220: 32-37.
3. Tokura Y, Mori T, Hino R: Psoriasis and other Th17-mediated skin diseases. J UOEH 2010; 32: 317-328.
4. van Lingen RG, van de Kerkhof PC, Seyger MM, de Jong EM, van Rens DW, Poll MK, Zeeuwen PL, van Erp PE: CD26/dipeptidylpeptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008; 158: 1264-1272.
5. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A: Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis. Dermatology 2009; 219: 209-218.
6. Garcia-Valladares I, Cuchacovich R, Espinoza LR: Comparative assessment of biologics in treatment of psoriasis: Drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 2011; 5: 41-49.
7. Saurat JH, Guérin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM: High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: Associated clinical and economic outcomes in real-world practice. Dermatology 2010; 220: 128-137.
8. Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, Lendeckel U, Wolke C, Neubert K, Faust J, Fuchs P, Reinhold D, Thielitz A, Täger M: Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009; 47: 253-261.